Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 11Lung Neoplasms 5Breast Neoplasms 2Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Advanced Solid Tumors 1

Interventions

Etoposide 4Carboplatin 4atezolizumab 3pembrolizumab 2Radiotherapy 2tislelizumab 1sintilimab 1irinotecan sucrosofate 1durvalumab 1camrelizumab 1apatinib 1anlotinib 1amrubicin 1Platinum 1Paclitaxel 1Observation 1NPI 2358 1Immunotherapy 1Immune Checkpoint Inhibitors 1Epirubicin 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Cancer Extensive Stage × amrubicin × Clear all
NCT03253068 2020-05-19

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Wakayama Medical University

Phase 2 Unknown
25 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡